Larimar Therapeutics LRMR
NASDAQ LRMR
$2.42 -0.02 (-0.82%)
At close: Oct 21, 2026 · 4:00 PM EDT

Larimar Therapeutics (LRMR) Preferred Stock Liabilities (2013)

Updated

Larimar Therapeutics (LRMR) recorded Preferred Stock Liabilities of $103.8 million in Q4 2013.

Analysis

Larimar Therapeutics (LRMR) Preferred Stock Liabilities (2013) Analysis & Trends

  • Across earlier years, Preferred Stock Liabilities came in at $62.79 million in FY2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn -
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn -
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn -
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn -
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -
10 Larimar Therapeutics 252.95 Mn -354.12 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2013 103.80 Mn
API Access

Larimar Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=LRMR&period=max&api_key=YOUR_API_KEY